BLA 125360 · Merz Pharms
Xeomin
Incobotulinumtoxina · Injection · Acetylcholine Release Inhibitor; Neuromuscular Blocker
NovelLast checked: Nov 20, 2026Latest source record: Jun 25, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2010
Jul 30, 2010
Approved uses
10
Original approval plus efficacy supplements
Registered trials
183
57 Phase 3, 17 recruiting
FAERS reports
5,818
787 serious, 110 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DISTANT SPREAD OF TOXIN EFFECT Postmarketing reports indicate that the effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including lower limb spasticity in...
What it is approved for
From the label in effect Jul 10, 2026.
XEOMIN is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of: Chronic sialorrhea in patients 2 years of age and older ( 1.1 ) Upper limb spasticity in patients 2 years of age and older ( 1.2 ) Cervical dystonia in adults ( 1.3 ) Blepharospasm in adults ( 1.4 ) the appearance of upper facial lines in adults: moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity ( 1.5 ) moderate to severe horizontal forehead lines associated with frontalis muscle activity ( 1.5 ) moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity ( 1.5 ) 1.1 Chronic Sialorrhea XEOMIN is indicated for the treatment of chronic sialorrhea in patients 2 years of age and older. 1.2 Upper Limb Spasticity XEOMIN is indicated for the treatment of upper limb spasticity in patients 2 years of age and older. 1.3 Cervical Dystonia XEOMIN is indicated for the treatment of cervical dystonia in adult patients. 1.4 Blepharospasm XEOMIN is indicated for the treatment of blepharospasm in adult patients. 1.5 Upper Facial Lines (Glabellar Lines, Horizontal Forehead Lines, and Lateral Canthal Lines) XEOMIN is indicated in adult patients for the temporary improvement in the appearance of upper facial lines: moderate to severe glabellar lines (GL) associated with corrugator and/or procerus muscle activity moderate to severe horizontal forehead lines (HFL) associated with frontalis muscle activity moderate to severe lateral canthal lines (LCL) associated with orbicularis oculi muscle activity.
Mechanism: XEOMIN blocks cholinergic transmission at the neuromuscular and salivary neuroglandular junction by inhibiting the release of acetylcholine from peripheral cholinergic nerve endings. This inhibition occurs according to the following sequence: neurotoxin binding to cholinergic nerve terminals, internalization of the neurotoxin into the nerve terminal, translocation of the light-chain part of the molecule into the cytosol of the nerve terminal, and enzymatic cleavage of SNAP25, a presynaptic target protein essential for the release of acetylcholine. In both muscles and glands, impulse...
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 25, 2026 Supplement 108 · Efficacy LetterLabel
- Jul 5, 2024 Supplement 99 · Efficacy
- Dec 18, 2020 Supplement 86 · Efficacy · priority review LabelLetter
- Aug 18, 2020 Supplement 78 · Efficacy LetterLabel
- May 10, 2019 Supplement 74 · Efficacy LetterLabel
- Jul 3, 2018 Supplement 73 · Efficacy · priority review LabelLetter
- Dec 22, 2015 Supplement 67 · Efficacy LabelLetter
- Jul 20, 2011 Supplement 7 · Efficacy Label
- Jul 30, 2010 Supplement 1 · Efficacy LabelLetter
- Jul 30, 2010 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
3 products under this application
- Xeomin · incobotulinumtoxinA 200 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
- Xeomin · incobotulinumtoxinA 50 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
- Xeomin · incobotulinumtoxinA 100 UNITS/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Incobotulinumtoxina" as an intervention, any sponsor and status, largest first.
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018700 · 997 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Episodic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 110 sites in all
- A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic MigrainePivotal-lookingActive, not recruiting
Merz Therapeutics GmbHIndustry
NCT07018713 · 808 participants · Start Aug 21, 2025 · Primary completion Mar 2027
Drug: Xeomin; Placebo · For: Chronic Migraine
Sites: Chandler, Arizona; Phoenix, Arizona; Little Rock, Arkansas · 111 sites in all
- Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown LinesPivotal-lookingCompleted
Merz Pharmaceuticals GmbHIndustry
NCT00512135 · 801 participants · Start Jun 18, 2007 · Primary completion Dec 28, 2009
Drug: IncobotulinumtoxinA (Xeomin) (20 units) · For: Glabellar Lines
Sites: Los Angeles, California; Englewood, Colorado; Aventura, Florida · 25 sites in all
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study IPivotal-lookingCompleted
Croma-Pharma GmbHIndustry
NCT02677298 · 784 participants · Start Mar 2, 2016 · Primary completion Nov 23, 2016
Drug: Botulinum Toxin A; Placebo and 1 more · For: Glabellar Frown Lines
Sites: Birmingham, Alabama; Encino, California; San Francisco, California · 18 sites in all
- Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain InjuryPivotal-lookingActive, not recruiting
Merz Pharmaceuticals GmbHIndustry
NCT03992404 · 603 participants · Start Sep 16, 2019 · Primary completion Jun 19, 2025
Drug: NT 201; Placebo · For: Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury
Sites: Birmingham, Alabama; Little Rock, Arkansas; Downey, California · 71 sites in all
- Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in CombinationPivotal-lookingCompleted
Galderma R&DIndustry
NCT04247074 · 413 participants · Start Feb 10, 2020 · Primary completion Oct 2, 2020
Drug: botulinum toxin neuromodulator; Placebo · For: Glabellar Frown Lines (GL); Lateral Canthal Lines (LCL)
Sites: Encino, California; Santa Monica, California; West Hollywood, California · 12 sites in all
- Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study III (BLESSIII)Pivotal-lookingCompleted
Croma-Pharma GmbHIndustry
NCT03985982 · 410 participants · Start Apr 29, 2019 · Primary completion Dec 4, 2019
Drug: Botulinum Toxin A; Placebo and 1 more · For: Glabellar Frown Lines
Sites: Nashville, Tennessee
- To Evaluate HU-045 With Moderate to Severe Glabellar LinesPivotal-lookingRecruiting
Huons BiopharmaIndustry
NCT07870694 · 390 participants (planned) · Start Sep 3, 2026 · Primary completion May 2027
Drug: HU-045; Xeomin® · For: Glabellar Lines
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective1,876
- off label use1,218
- therapeutic response decreased761
- injection site pain343
- overdose237
- product preparation issue216
- injection site swelling213
- headache195
- product use in unapproved indication195
- pain181
- injection site erythema140
- eyelid ptosis134
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 2 |
| 2011 | 16 |
| 2012 | 66 |
| 2013 | 16 |
| 2014 | 20 |
| 2015 | 174 |
| 2016 | 354 |
| 2017 | 242 |
| 2018 | 368 |
| 2019 | 315 |
| 2020 | 394 |
| 2021 | 542 |
| 2022 | 555 |
| 2023 | 651 |
| 2024 | 830 |
| 2025 | 754 |
| 2026 | 519 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xeomin (Incobotulinumtoxina)
2024 spending
$3.6M
Beneficiaries
1,293
3,207 claims
Per beneficiary
$2,815
$602.51 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $1,004,156 |
| 2021 | $1,282,706 |
| 2022 | $2,236,227 |
| 2023 | $2,996,460 |
| 2024 | $3,639,657 |
Part B: Xeomin (Incobotulinumtoxina) · HCPCS J0588
2024 spending
$28.6M
Beneficiaries
12,164
29,626 claims
Per beneficiary
$2,355
2024 ASP limit $5.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $17,986,978 |
| 2021 | $19,592,905 |
| 2022 | $21,780,968 |
| 2023 | $25,678,441 |
| 2024 | $28,640,185 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Botulinum toxin type A for facial wrinkles.
Camargo CP, Xia J, Costa CS, et al. · Cochrane Database Syst Rev 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Systematic Review and Meta-Analysis of Secondary Treatment Failure and Immunogenicity With Botulinum Neurotoxin A in Multiple Indications.
Walter U, Albrecht P, Carr W, et al. · Eur J Neurol 2025 · Systematic Review, Meta-Analysis
- Botulinum toxin type A therapy for cervical dystonia.
Rodrigues FB, Duarte GS, Marques RE, et al. · Cochrane Database Syst Rev 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- IncobotulinumtoxinA for Aesthetic Indications: A Systematic Review of Prospective Comparative Trials.
Prager W, Nogueira Teixeira D, Leventhal PS · Dermatol Surg 2017 · Comparative Study, Systematic Review
- Nonsurgical treatment for upper eyelid retraction in patients with inactive Graves' orbitopathy.
Vokurka Topljak S, Galiot Delik M, Mandik K, et al. · Int Ophthalmol 2023 · Randomized Controlled Trial
- IncobotulinumtoxinA Injection for Temporomandibular Joint Disorder.
Patel AA, Lerner MZ, Blitzer A · Ann Otol Rhinol Laryngol 2017 · Randomized Controlled Trial
Sponsor: Merz Pharms
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.